###### Strengths and limitations of this study

-   Randomised trial comparing two emerging radiotherapy regimens for prostate cancer.

-   Technological substudy seeking to implement MRI only planning.

-   Use of novel approaches such as automated plan assessment to ensure high-quality treatment.

-   Limitation is the use of a biochemical surrogate endpoint at 5 years rather than longer-term survival endpoints

Background {#s1}
==========

Stereotactic body radiotherapy for prostate cancer {#s1-1}
--------------------------------------------------

Prostate cancer (PC) has a major impact on the Australian population with 3500 deaths projected in 2018 and treatment costs to patients and the health system exceeding \$500 million by 2025.[@R1] The question at the heart of Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation (NINJA) is to compare two emerging and practice-changing schedules of radiotherapy that leverage state-of-the-art technology developments and our Australian clinical trial experience to make treatments safer, highly efficient and more convenient for patients. The first schedule is a five-fraction stereotactic body radiotherapy (SBRT monotherapy) approach.[@R3] The alternative regimen is 'virtual high-dose rate boost' (HDRB), non-invasively delivering brachytherapy-type doses.[@R4] Superiority of the latter schedule would validate the utility of dose escalation to improve outcomes. Similarity of outcomes in the former schedule would allow for major cost savings and reduced patient burden with reduction of treatment sessions from 40 to 5 (see [figure 1](#F1){ref-type="fig"}).

![Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation trial schema. ADT, androgen deprivation therapy; HDRB, high-dose rate boost; SBRT, stereotactic body radiotherapy.](bmjopen-2019-030731f01){#F1}

Conventional radiotherapy regimens for PC are given five times per week for up to nine consecutive weeks.[@R5] Recent results from large non-inferiority studies including substantial Australian input has helped establish a 4-week moderately hypofractionated schedule as an alternative approach.[@R6] Building on this, large series are showing excellent outcomes with regimens giving as few as five radiotherapy fractions, using higher daily doses of radiotherapy.[@R9] A 477 patient series with median follow-up of 7 years showed 89.6% biochemical disease control with late grades 2 and 3 genitourinary (GU) toxicity low at 9% and 1.7%, respectively.[@R11] Grade 2 gastrointestinal (GI) toxicity was similarly favourable at 4.1%. Our Stereotactic Prostate Adaptive Radiotherapy with Kilovoltage intrafraction monitoring (SPARK) phase II study used a five-fraction prostate SBRT monotherapy in conjunction with intrafraction motion management to assess the dosimetric impact of increasing the accuracy of radiotherapy dose delivery.[@R3]

Following on from this experience, several randomised studies are currently underway exploring similar stereotactic regimens, where much higher daily doses of radiotherapy are given in between five and seven visits ([table 1](#T1){ref-type="table"}). The Scandinavian HYPO-RT-PC study completed accrual in 2015, and presented early toxicity data in 2016 showing no significant differences between the control and SBRT arms.[@R13] Initial efficacy results from this study were presented in 2018, showing no differences between the two arms. Recent guidelines have incorporated prostate SBRT monotherapy as a treatment option for centres experienced in this technique.[@R15] Bringing this together, although SBRT monotherapy can currently be considered investigational, it is likely to gain wider acceptance as a standard treatment option in the near future. Hence, our plan is to commence NINJA as a randomised phase II study, but to convert to a fully powered phase III study with SBRT monotherapy as the control arm as the evidence base continues to mature.

###### 

Selected current and pending randomised trials investigating stereotactic body radiotherapy for prostate cancer

  Trial                         Control arm(s)         Experimental arm   N      Progress
  ----------------------------- ---------------------- ------------------ ------ ------------------------
  HYPO-RT-PC (ISRCTN45905321)   78 Gy/39               42.7 Gy/7          1200   Results presented 2018
  PACE (NCT01584258)            78 Gy/39 or 62 Gy/20   36.25 Gy/5         858    Completed accrual
  HEAT (NCT01794403)            70.2 Gy/26             36.25 Gy/5         456    Accruing
  NRG GU005 (NCT03367702)       70 Gy/28               36.25 Gy/5         622    Accruing

Strong evidence exists for superior disease control through the use of a brachytherapy boost compared with conventional radiotherapy.[@R16] Despite this, the use of brachytherapy continues to decline, partly due to concerns regarding higher risks of significant late GU toxicity.[@R18] Also, the lack of evidence for improved disease control translating to improved survival has limited uptake, although the poor sensitivity of conventional staging investigations may contribute to superior local control being overwhelmed by undiagnosed micro-metastatic disease. The emergence of PSMA-PET as a more sensitive and specific staging modality makes revisiting the radiotherapy dose-escalation question highly relevant.[@R19] An alternative approach to brachytherapy is a 'virtual HDRB' where two to three large doses designed to mimic HDRB are delivered via stereotactic techniques with an additional fractionated external beam radiation therapy (EBRT) component. Relatively small virtual HDRB series with nearly 4-year follow-up have shown this approach to be feasible, although often using specialised equipment such as the Cyberknife platform.[@R21] Virtual HDRB has also been proven feasible in the setting of multicentre phase II trial in Australia, with 135 men enrolled on the PROMETHEUS trial (ACTRN12615000223538) where two fractions of 9.5--10 Gy are followed by an EBRT component of either 46 Gy in 23 or 36 Gy in 12 fractions. Early data from PROMETHEUS show no grades 2--3 late GI toxicity after 24 months and grade 2 late GU toxicity prevalence rates of \<7% out to 3 years. Promising efficacy signals are also becoming evident, with almost ablative prostate-specific antigen (PSA) levels being observed consistent with excellent disease response.[@R23]

Virtual HDRB may represent a significant biological dose escalation compared with SBRT monotherapy. Assuming PC has an alpha beta ratio of 1.5 Gy, 40 Gy in five fractions and virtual HDRB would be equivalent to 110 and 120 Gy in 2 Gy equivalent fractions, respectively. Modelling of RCT data suggests that each extra grey in dose translates to \~2% improvement in disease control.[@R24] The virtual HDRB approach also acknowledges the possibility of heterogeneity in the alpha--beta ratio, and therefore potentially allows for some variation in fraction size sensitivity within and between tumours. A reasonable question would be whether the excellent results seen with HDR brachytherapy boost could be safely translated into the stereotactic setting on the basis of this increase in biological dose delivery. This is the fundamental question which drives NINJA.

Knowledge-based planning {#s1-2}
------------------------

Knowledge-based planning (KBP) has the potential to simultaneously improve and automate the radiotherapy planning process. KBP uses previous cases to build a model of an optimal treatment plan which can then be applied to the current patient. Previous work suggests that KBP can provide faster and frequently better plans,[@R25] but this has not been prospectively assessed in a multicentre fashion. NINJA provides an ideal opportunity for this.

Radiotherapy plan quality is critically important in achieving optimal treatment outcomes. The Australia-led Trans-Tasman Radiation Oncology Group (TROG) 02--02 study for patients with locally advanced head and neck cancer showed that non-protocol compliant plans had a locoregional control and overall survival decrement of 24% and 20%, respectively.[@R26] Via TROG, Australia has become leaders in the use of approaches such as stringent credentialing and RT review (RTR) of RT contours and plans, with work in PC subsequently showing very low rates of protocol deviations both in the definitive prostate and post-prostatectomy irradiation scenarios.[@R27]

An issue with the current RTR process is that although a plan can be deemed satisfactory, it is difficult to determine whether it could be improved. As treatment techniques evolve, satisfying the dose constraints in clinical trial protocols can become progressively easier. KBP has emerged as a promising approach to assess and improve plan quality. In KBP, a model is developed using a range of patient anatomies and target volumes. This can then be rapidly applied to a new case to either generate a plan de novo or to compare with a conventional plan. The Radiation Therapy Oncology Group (RTOG) 0126 prostate cohort was selected to study treatment plan quality variations. This work examined the high-dose Intensity Modulated Radiation Therapy (IMRT) patients using a KBP model to identify the plans that best met the dosimetric aims of the protocol.[@R29] Focusing on Grade 2+late rectal toxicities with an outcomes-validated normal tissue complication probability model, the high-dose arm of RTOG 0126 patients treated with IMRT patients had a 15.1% cumulative incidence of Grade 2+rectal complications.[@R30] KBP plans were predicted to lead to a 4.7% risk reduction in this rate, which therefore may have cut this incidence by a third. The observed quality variations in RTOG 0126 give the strongest evidence yet that suboptimal planning is a critical problem in multi-institutional radiotherapy clinical trials and in the wider practice of radiotherapy. KBP has yet to be robustly assessed in a multicentre fashion, where the heterogeneity of planning systems and personnel would be expected to be greatest.

MRI radiotherapy planning {#s1-3}
-------------------------

CT is widely used for radiotherapy dosimetry calculation because of the ability to directly measure electron density. Our team has validated the use of MRI to create a substitute CT (sCT) which can then be used for accurate dose calculation.[@R31] The superior soft tissue resolution of MRI, absence of radiation dose and reduction in image artefacts means that if the dose calculation problem could be solved, standard CT-based planning would be rendered obsolete.[@R32]

Many centres now acquire both a CT and a MRI scan for each patient, but co-registration of these datasets introduces significant error mostly under the influence of bladder filling and varying rectal distension. An attractive alternative would be to create a sCT from the MRI dataset to allow RT dose calculation. Our team has developed a hybrid atlas-voxel-based technique of sCT generation which showed high agreement in both mean monitor units (0.3%±SD 0.8%) and dose delivery (three-dimensional (3D) gamma pass rate at 2 mm/2% level of 100%±SD 0%.[@R31] A group of Swedish centres have shown similar findings in a retrospective, multicentre study,[@R33] and our group is prospectively evaluating this approach in two centres (HIPSTER study---ACTRN12616001653459). Given the advantages of MRI for PC, and the improving access to MRI in Australia (including radiotherapy departments with dedicated planning MRI facilities), this is another area ripe for wider assessment, implementation and eventual broader application.

Summary {#s1-4}
-------

NINJA is a combined phase II/III multicentre study of 472 men randomised to two novel radiotherapy schedules. The hypotheses are that NINJA will advance (1) biochemical clinical control (BCC) of PC, (2) treatment planning via automation and (3) planning imaging methodology.

### Aim 1: radiobiological dose escalation {#s1-4-1}

The escalated radiation dose delivered using a virtual HDRB approach achieves superior disease control compared with a SBRT monotherapy alternative.

### Aim 2: KBP advantage {#s1-4-2}

The treatment plans using KBP will be dosimetrically superior to traditional manual planning approaches.

### Aim 3: MRI only planning {#s1-4-3}

MRI will give dosimetry similar to standard CT planning.

Methods/design {#s2}
==============

Study design {#s2-1}
------------

The study design is a prospective randomised phase III trial which conforms to the Standard Protocol Items: Recommendations for Interventional Trial (SPIRIT) guidelines. We will initially enrol 150 men to demonstrate accrual feasibility as well as addressing the KBP and MRI planning aims, prior to proceeding with total accrual as a randomised phase III controlled trial.

-   *Stage one*: Feasibility indicators--- activate at least 10 centres, and accrue 50 patients within 18 months of central HREC approval.

-   *Stage two*: Accrue total of 150 patients for randomised phase II component within 36 months of approval. Analyses of KBP and MRI planning components.

-   *Stage three*: Complete accrual of 472 patients to the two SBRT arms.

Key trial eligibility criteria {#s2-2}
------------------------------

Unfavourable intermediate or favourable high-risk PC (any combination of ISUP 3--5 and/or cT2b/T2c/T3aN0 and/or PSA 10--20 in the absence of other high-risk factors, ie, T3b/T4, PSA \>20). For high-risk patients, PSMA-PET staging prior to study entry showing N0M0 disease. Prostate volume \<100 cc, and patients can only be randomised after a plan has been generated showing that protocol compliant treatment can be performed.

Pre-treatment {#s2-3}
-------------

All patients will receive a total of 6 months of androgen deprivation therapy (ADT).[@R34] The use of PSMA-PET staging for high-risk men, and criteria to exclude very high-risk features should minimise any potential additive benefits of longer course ADT in this population. Both CT and MRI planning scans will be performed for the first 10 patients at each centre and phasing out CT for centres involved in MRI planning aspect of NINJA. Rectal displacement (eg, SpaceOAR, Rectafix, Rectal Balloon) is encouraged, but not mandated.[@R36] Urethral positional estimation via temporary catheterisation or equivalent approaches such as high-resolution sagittal MRI can be performed. Erectile sparing RT plans for men with adequate baseline International Index of Erectile Function (IIEF) and desire to maintain erectile function can be used.[@R37] Centres will be credentialed for MRI planning via their first five patients being primarily planned off the CT, but with sCT generation and confirmation of accurate dosimetry. The next 10 patients will have planning performed on sCT and confirmed on planning CT. Subsequent patients will omit a planning CT, be planned on sCT and have confirmation of accurate dosimetry on treatment using a centrally approved approach, for example, Electronic Portal Imaging Device (EPID) dosimetry[@R38] or in vivo dosimetry.[@R39]

Time-dose-fractionation planning details {#s2-4}
----------------------------------------

Clinical target volume (CTV): Entire prostate and proximal 10 mm of seminal vesicles. No elective nodal irradiation permitted.

Planning target volume (PTV): For SBRT treatments, 3 mm uniform expansion from CTV. For Virtual HDRB 36 Gy in 12 fraction component, 7 mm uniform expansion from CTV.

*SBRT Monotherapy arm*: 40 Gy in five fractions delivered two to three times per week, prescribed to CTV D95%.

*Virtual HDRB boost arm*: 20 Gy in two fractions prescribed to CTV D95% delivered once a week followed by a 2-week break and then 36 Gy in 12 fractions delivered five times per week prescribed to PTV D95%. See [table 2A--C](#T2){ref-type="table"} for dose constraints, and [figure 2](#F2){ref-type="fig"} for an example of the SBRT dosimetry.

![Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation dosimetry example showing very conformal nature of high-dose treatment to the PTV. CTV, clinical target volume; IPA, internal pudendal artery; NVB, neurovascular bundle; PTV, planning target volume.](bmjopen-2019-030731f02){#F2}

###### 

Target volume objectives and Organs At Risk (OAR) constraints---40 Gy in 5\#

  -------------------------------------------------------------------------------------
  Objective             Protocol            Minor variation       Major variation
  --------------------- ------------------- --------------------- ---------------------
  CTVp D95%             ≥40.0               38≤40 Gy              \<38 Gy

  PTV_4000 D95%         ≥36 Gy              34.44≤36 Gy           \<34.44 Gy

  PTV_4000 D98%         ≥34.44 Gy\          32.72≤34.44 Gy        \<32.72 Gy
                        (95% of 36.25 Gy)                         

  PTV_4000 D2%          ≤42 Gy              42--42.8 Gy           \>42.8 Gy

  Dmax (0.1cc)          ≤42.8 Gy            42.8--44 Gy           \>44 Gy

  Dmax (0.1cc)          Not in OAR          NA                    In OAR

  **Constraint**        **Protocol**        **Minor variation**   **Major variation**

  RECTUM V40 Gy         ≤0.1cc              NA                    \>0.1cc

  RECTUM V36 Gy         ≤1cc                \>1--2cc              \>2cc

  RECTUM V32 Gy         ≤10%                \>10%--20%            \>20%

  RECTUM V20 Gy         ≤40%                \>40%--50%            \>50%

  URETHRA_PRV V42 Gy    ≤0.1cc              NA                    \>0.1cc

  BLADDER V40 Gy        ≤2cc                \>2--3cc              \>3cc

  BLADDER V36 Gy        ≤10cc               \>10--20cc            \>20cc

  BLADDER V32 Gy        ≤10%                \>5%--10%             \>10%

  BLADDER V20 Gy        ≤40%                \>40%--50%            \>50%

  PENILE BULB V36 Gy    ≤0.1cc              NA                    \>0.1cc

  PENILE BULB V20 Gy    ≤3cc                \>3--5cc              \>5cc

  FEM HEAD V30 Gy       ≤0.1cc              NA                    \>0.1cc

  FEM HEAD V20 Gy       ≤10cc               \>10--15cc            \>15cc

  SIGMOID V40 Gy        ≤0.1cc              NA                    \>0.1cc

  SIGMOID V36 Gy        ≤2cc                \>2--3cc              \>3cc

  **Constraint**                                                  

  SMALL BOWEL V30 Gy    ≤1cc                NA                    \>1cc

  SMALL BOWEL V25 Gy    ≤20cc               \>20--40cc            \>40cc

  Conformity index\*    ≤1.1                \>1.1--1.2            \>1.2

  Int. dose spillage†   ≤4                  \>4--5                \>5

  MU/cGy ratio‡         ≤3                  \>3--4                \>4
  -------------------------------------------------------------------------------------

\*Optional---volume receiving 36.25 Gy/volume of PTV.

†Optional--ratio of volume receiving 36.25 Gy: 18.13 Gy.

‡Optional--ratio of Monitor Units (MU) delivered per fraction divided by 800 (the number of centiGray (cGy) prescribed/fraction).

CTV, clinical target volume; PTV, planning target volume.

###### 

Target volume objectives and organs at risk constraints---virtual high-dose rate boost, stereotactic body radiotherapy component 20 Gy in two fractions

  Objective             Protocol     Minor variation   Major variation
  --------------------- ------------ ----------------- -----------------
  CTVp D95%             ≥20 Gy       18≤20 Gy          \<18 Gy
  PTV_2000 D95%         ≥18 Gy       17≤18 Gy          \<17 Gy
  PTV_2000 D98%         ≥17 Gy       16≤17 Gy          \<16 Gy
  PTV_2000 D2%          ≤21 Gy       \>21--21.4 Gy     \>21.4 Gy
  Dmax (0.1cc)          ≤21.4 Gy     \>21.4--22 Gy     \>22 Gy
  Dmax (0.1cc)          Not in OAR   NA                In OAR
  **Constraint**                                       
  RECTUM V20 Gy         ≤0.1cc       NA                \>0.1cc
  RECTUM V16 Gy         ≤1cc         \>1--2cc          \>2cc
  RECTUM V14 Gy         ≤10%         \>10%--20%        \>20%
  RECTUM V10 Gy         ≤40%         \>40%--50%        \>50%
  URETHRA_PRV V21 Gy    ≤0.1cc       NA                \>0.1cc
  BLADDER V20 Gy        ≤2cc         \>2--3cc          \>3cc
  BLADDER V18 Gy        ≤10cc        \>10--20cc        \>20cc
  BLADDER V16 Gy        ≤10%         \>10%--15%        \>15%
  BLADDER V10 Gy        ≤40%         \>40%--50%        \>50%
  PENILE BULB V18 Gy    ≤0.1cc       NA                \>0.1cc
  PENILE BULB V10 Gy    ≤3cc         \>3--5cc          \>5cc
  FEM HEAD V15 Gy       ≤0.1cc       NA                \>0.1cc
  FEM HEAD V10 Gy       ≤10cc        \>10--15cc        \>15cc
  SIGMOID V20 Gy        ≤0.1cc       NA                \>0.1cc
  SIGMOID V18 Gy        ≤2cc         \>2--3cc          \>3cc
  SMALL BOWEL V15 Gy    ≤1cc         NA                \>1cc
  SMALL BOWEL V10 Gy    ≤20cc        \>20--40cc        \>40cc
  Conformity index\*    ≤1.1         \>1.1--1.2        \>1.2
  Int. dose spillage†   ≤4           \>4--5            \>5
  MU/cGy ratio‡         ≤3           \>3--4            \>4

\*Optional---volume receiving 18 Gy/volume of PTV.

†Optional---ratio of volume receiving 18 Gy: 9 Gy.

‡Optional---ratio of MU delivered per fraction divided by 1000 (the number of cGy prescribed/fraction).

CTV, cilinical target volume; PTV, planning target volume.

###### 

Target volume objectives and organs at risk constraints---virtual HDRB, EBRT component 36 Gy in 12 fractions

  Objectives                 Protocol   Minor variation   Major variation
  -------------------------- ---------- ----------------- -----------------
  PTV_3600 D95%              ≥36 Gy     34.2≤36 Gy        \<34.2 Gy
  PTV_3600 D98%              ≥34.2 Gy   32.4≤34.2 Gy      \<32.4 Gy
  PTV_3600 D2%               ≤37.8 Gy   \>37.8--38.5 Gy   \>38.5 Gy
  PTV_3600 (0.1cc)           ≤38.5 Gy   \>38.5--39.6 Gy   \>39.6 Gy
  **Constraint**                                          
  Small Bowel Dmax (0.1cc)   ≤36 Gy     \>36--38 Gy       \>38 Gy
  Fem Head Dmax (0.1cc)      ≤25 Gy     \>25--35 Gy       \>35 Gy
  Rectum V30 Gy              ≤25%       \>25%--35%        \>35%
  Bladder V32 Gy             ≤25%       \>25%--35%        \>35%

CTV, cilical target volume; PTV, planning target volume.

Quality assurance {#s2-5}
-----------------

Centre credentialing will include submission of a 'Virtual HDRB' treatment plan for a patient to ensure accurate contouring and protocol compliant dose delivery. The initial KBP model will be generated from phase 2 SPARK and PROMETHEUS trials, but will be updated as NINJA proceeds. All cases will be submitted for KBP comparison, and an automated report to be returned within 24 hours. RTR will occur for all patients on trial.

Treatment delivery {#s2-6}
------------------

All patients require intra-prostatic markers, and both inter-fraction and intra-fraction motion management strategies to ensure accurate treatment delivery. For intra-fraction motion assessment, numerous 'RT' approaches are acceptable (eg, KIM, Calypso, Cyber-knife). In all instances, translational movements to be corrected to 0 mm threshold prior to commencing treatment. Rotational corrections do not need to be applied due to minimal dosimetric impact from such motion.[@R40]

Outcome reporting {#s2-7}
-----------------

Indicators of feasibility, accuracy, impact on replanning, and other qualitative and quantitative markers of KBP and MRI planning will be collected. Patient-reported outcomes (PROs) to include baseline and serial PROs (IIEF, Expanded Prostate Cancer Index Composite (EPIC)), physician toxicity grading (CTC AE v5), PSA and any sites of confirmed disease relapse or death due to any cause. If the prevalence of CTC AE grade 3 GI or GU toxicities exceeds 10% at any stage, the trial will be halted for safety assessment. A SPIRIT flowchart is presented in [table 3](#T3){ref-type="table"}.

###### 

Schedule of assessments as per StandardProtocol Items: Recommendations for Interventional Trial guidelines

  Assessment                Pre-treatment   Treatment   Follow-up                   
  ------------------------- --------------- ----------- ----------- ------- ------- -------
  Informed consent          **✓**                                                   
  Eligibility assessment    **✓**                                                   
  Staging investigations¶   **✓**                                                   
  Clinical examination                      **✓**                   **✓**   **✓**   
  Adverse event                             **✓**       **✓**       **✓**   **✓**   
  PSA                                       **✓**                   **✓**   **✓**   
  PRO EPIC 26+/-IIEF 25                     **✓**                   **✓**           **✓**

\*To be done within 60 days of registration.

†To be done no more than 2 weeks post-registration and within 4 weeks of starting treatment.

‡To be performed between 6 weeks post-SBRT treatment completion.

§From commencement of androgen deprivation therapy.

¶Note that PSMA-PET is mandated for high-risk patients. Whole body bone scan with CT or MRI of the pelvis ± abdomen are acceptable for unfavourable intermediate risk patients.

EPIC, Expanded Prostate Cancer Index Composite; PSA, prostate-specific antigen; SBRT, stereotactic body radiotherapy.

Statistical considerations {#s2-8}
--------------------------

The statistical justification required to achieve the primary efficacy endpoint (aim 1) is as follows. BCC is a hybrid of biochemical failure via the nadir plus two definition, deployment of salvage treatments, or the detection of local, regional or metastatic relapse via imaging. Using a similar endpoint as well as a short course of ADT, the CHHiP study 60 Gy arm had 90.2% and 84.2% BCC for intermediate-risk and high-risk patients, respectively.[@R41] The Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy study also included intermediate-risk and high-risk men, managed with 12 months of ADT, and the experimental arm delivered 46 Gy in 23 fractions of EBRT alongside a LDR brachytherapy boost.[@R17] At 5 years, the BCC was 89% in the brachytherapy boost cohort, although with a higher-risk patient mix than we are going to accrue on this protocol. Allowing for differences in inter-trial comparisons, we estimate BCC \~86% in the standard SBRT arm. Similar data have been reported for single-arm SBRT monotherapy series.[@R12] For a superiority RCT design, we will aim for a HR of 0.5 in 5-year BCC for the virtual HDR arm that is, 93%. An HR of 0.5 is chosen because this translates to an absolute improvement of 7%, and any improvements less than this are unlikely to be clinically significant. With alpha 0.05, power of 80%, and dropout of 2% the required phase III sample size is 472 men.

For KBP (aim 2), we hypothesise that a replanning rate of \>15% would be clinically significant. Assuming an error rate of ±6%, at an alpha of 5%, 136 patients are required. Allow 10% dropout due to technical issues with a new planning paradigm: total of 150 cases. For MRI planning (aim 3), having ≥50% of centres involved in this aspect of NINJA completely transition to MRI only planning will be deemed a success.

Endpoints NINJA aim 1: radiobiological dose escalation {#s2-9}
------------------------------------------------------

For each patient visit, PSA, GU and GI RTOG physician graded toxicity and PROs using the EPIC instrument will be recorded. The acute toxicity will be measured each week of treatment, and 2 weeks after treatment completion. As severe acute toxicity is a surrogate for late toxicity, this will be the primary physician-reported toxicity outcome for this 3-year study. PROs will be at baseline, then 1-year, 3-year and 5-year marks. Biochemical control will be assessed with PSA testing at baseline, then every 6 months, with failure defined by the nadir plus 2 Phoenix definition. Clinical control consists of any evidence of relapse on imaging, or the initiation of salvage treatments. BCC is the combination of either biochemical or clinical events. BCC at 5 years will be the primary endpoint for aim 1.

Endpoint NINJA aim 2: KBP advantage {#s2-10}
-----------------------------------

KBP models will initially be developed for the SBRT monotherapy and virtual HDRB arms. The training sample for the NINJA KBP model will come from the SPARK and PROMETHEUS cohorts, and will be continuously improved during the NINJA trial. As new cases are accepted to the trial, they will be incorporated into the knowledge-based dose prediction models to broaden the geometric experience and improve future prediction accuracy. The NINJA KBP automated planning routines' performance will be validated on an independent validation sample of cases (holding back 20% of SPARK/PROMETHEUS cases) to ensure that the final KBP plans are effecting plans that match the dosimetric goals of the NINJA protocol.

All NINJA patients will have a plan generated as per local standard of care by the treating centre. If sites are capable of utilising KBP locally, they will be provided with the NINJA KBP routine. All plans will then be uploaded to TROG to be compared with a KBP-generated plan. If the site was submitting a manually generated plan, an automated report will be returned to the treating centre within 24 hours, at which time they can decide whether to proceed with their original manual plan or to replan based on the KBP recommendations. If the site utilises the NINJA KBP routine, a central quality check will be performed to ensure proper use of the model, but no further recommendation will be made to the submitting site. The utility of KBP will be assessed by recording the rate of replanning following receipt of the KBP plan.

Endpoint NINJA aim 3: -- MRI planning validation {#s2-11}
------------------------------------------------

This substudy will be for centres with access to MRI scanning with appropriate accessories such as a flat top couch. Patients will have a CT and a MRI performed in the planning position. Clinicians will contour all target volumes and organs at risk on the MRI. Sites who have not been validated for MRI-based planning will go through a credentialing phase, where the first five patients will have the planning processes assessed.[@R31] Following credentialing (or evidence of previously fulfilling this requirement), the MRI will be exported for remote generation of a sCT. A plan will then be created on the sCT, and copied onto the planning CT. The dosimetry of these will be compared at points within both the target volume and critical structures. If the isocentre dose is within 2% and 3D gamma comparison at 2%/2 mm criteria\>90% pass-rate for the entire scanned volume, then the sCT plan will be deemed accurate and used for patient treatment. After 10 such patients, centres will have the option of no longer performing a routine planning scan, but instead using in vivo dosimetry to confirm accurate dose delivery with the same criteria as for the sCT and planning CT comparison. The utility of MRI planning will be assessed via:

-   Accuracy---The proportion of plans where both the isocentre dose and gamma comparison are within the stated constraints. Deemed accurate if \>95%.

-   Feasibility---The proportion of sites who commence accrual who subsequently (a) achieve credentialing and (b) move successfully completely to MR only planning. Deemed feasible is ≥50% of sites.

Other substudies {#s2-12}
----------------

-   PROs using the IIEF and EPIC questionnaire.

-   Physician-reported toxicity using the CTC AE v5 scale.

-   Health economics---the cost-effectiveness profiles of the technologies being compared will be assessed in a cost consequence analysis. Resource use implications and impacts have utility both for decision-makers and for informing the phase III trial-based economic evaluation.

-   Erectile sparing RT (neurovascular bundles, pudendal arteries, penile bulb) and impact on PROs

-   Performance comparison between intrafraction motion management strategies

Patient and public involvement {#s2-13}
------------------------------

Many of the baseline requirements for NINJA have been informed by consumer feedback. The concept of improved treatment accuracy resonated with our consumer advisors, and as such is mandated for all patients in NINJA. Improved pre-treatment imaging with PSMA-PET will help define those most likely to benefit from aggressive management of their primary PC, an approach which our consumer advisors found essential for men with higher-risk disease. Our consumer advisors also prioritise PROs, and as such, PROs are one of our key endpoints. Our focus on assessing shorter, non-invasive radiotherapy treatment regimens which can be delivered on an outpatient basis also resonated with our consumer advisors.

Our consumer advisors will engage with consumer groups through organisations such as TROG, Australia New Zealand Urogenital Programme and Prostate Cancer Foundation of Australia to ensure broad consumer awareness of NINJA. The Trial Management Committee will continue to include our consumer advisors in ongoing discussions regarding accrual and toxicities to gain their perspective on any changes to the conduct of the trial which might be advisable.

NINJA is designed with numerous potentially practice changing outcomes; consumers will remain critical throughout the trial to maximise integration of these into wider clinical practice. Several of our team are very active on social media, which can make direct connexions with consumers about our findings. Many of our clinician CIs and AIs are regular speakers for local PC support groups.

Discussion {#s3}
==========

Prostate SBRT, KBP and MRI planning are all highly promising approaches with the potential to transform patient care far beyond the specific indication of definitive PC management. A large array of substudies will create new scientific knowledge and further inform best practice PC radiotherapy. The study plan seeks to assess and validate all of these approaches. More importantly, we aim to increase the capabilities of centres to perform such leading edge treatments. If validated, these approaches can be seamlessly integrated into routine clinical practice.

Conventional PC radiotherapy currently takes between 20 and 40 outpatient visits, so reducing this to between 5 and 14 will assist with access for patients as well as improve resource utilisation. Semiautomation of the planning process via KBP will both streamline processes and reduce variable plan quality. NINJA has been deliberately designed to facilitate treatment at small and larger institutes, crossing the divide between public and private as well as metropolitan and regional.

NINJA seeks to prospectively assess and validate promising new technologies as part of a randomised study comparing two novel prostate RT regimens. The research pathway established can serve as a template for future attempts to explore promising technological innovations in a cost-effective manner. Beyond the geographical sector and regional collaborations, NINJA brings together multiple states, as well as disciplines in clinical, technical and research fields.

Supplementary Material
======================

###### Reviewer comments

###### Author\'s manuscript

The study sponsor is the Trans-Tasman Radiation Oncology Group (TROG). The full protocol is available through TROG. We acknowledge the contributions of our consumer advisors Steve McCluskey and Russell Flank for their contributions to this clinical trial design.

**Contributors:** JM and MS conceived of the study. JM, MS, JS and DP were responsible for protocol drafting and data management plan. JM, PK, SS, PG, DC, KM, JD, DP, PC, NM, AR, JL, JS, CO, CIT, DGM, JM, KHT, LH, PR, AH, TL, TH and MS were involved in the study design, acquisition of competitive grant funding and helped to draft this manuscript. JM, PK, SS, PG, DC, KM, JD, DP, PC, NM, AR, JL, JS, CO, CIT, DGM, JM, KHT, LH, PR, AH, TL, TH and MS will remain involved in the conduct and reporting of the study, and have read and approved the final manuscript.

**Funding:** This study underwent competitive peer review by the National Health and Medical Research Council (NHMRC) and was awarded governmental Cancer Australia funding (APP1158455). Additional seed funding was provided by mundipharma.

**Competing interests:** None declared.

**Patient consent for publication:** Not required.

**Ethics approval:** This study has received Ethical approval from the South West Sydney Local Health District Human Research Ethics Committee (approval number HREC/18/LPOOL/420). All patients will sign a Participant Information Consent Form prior to being randomised and treated on this study.

**Provenance and peer review:** Not commissioned; externally peer reviewed.
